Astellas Pharma Inc. and UMN Pharma Inc. announced today that the both companies entered into a memorandum of understandings for UMN-0501 and UMN-0502, which are cell culture based influenza vaccine programs developed by UMN Pharma, to co-develop and exclusively commercialize in Japan, on August 16, 2010. A definitive agreement is planned to be concluded in September.